Insider · CIK 0002141314
Matthew Gregory Cohen
Files at ARWR (ARROWHEAD PHARMACEUTICALS, INC.). First filing -, latest -.
In brief
Matthew Gregory Cohen files SEC Form 4 as director at ARWR (ARROWHEAD PHARMACEUTICALS, INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Matthew Gregory Cohen has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 1 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | AGrant or award Common Stock | +11,882 | $0.00 | $0 | 11,882 | Jun 17, 2026 |
Questions about Matthew Gregory Cohen
Answered from the filings on this page, as of the latest one.
Is Matthew Gregory Cohen buying or selling?
Matthew Gregory Cohen has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Matthew Gregory Cohen's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Matthew Gregory Cohen has 0.
Where does Matthew Gregory Cohen file Form 4?
Matthew Gregory Cohen has filed Form 4 at ARWR (ARROWHEAD PHARMACEUTICALS, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.